JP2019517523A - 肝線維症を治療する方法 - Google Patents

肝線維症を治療する方法 Download PDF

Info

Publication number
JP2019517523A
JP2019517523A JP2018563453A JP2018563453A JP2019517523A JP 2019517523 A JP2019517523 A JP 2019517523A JP 2018563453 A JP2018563453 A JP 2018563453A JP 2018563453 A JP2018563453 A JP 2018563453A JP 2019517523 A JP2019517523 A JP 2019517523A
Authority
JP
Japan
Prior art keywords
inhibitor
substituted
unsubstituted
compounds
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018563453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517523A5 (enExample
Inventor
ミヤオ，ジェンホワ
チャロ，イスラエル
Original Assignee
ケモセントリックス， インコーポレイテッド
ケモセントリックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス， インコーポレイテッド, ケモセントリックス， インコーポレイテッド filed Critical ケモセントリックス， インコーポレイテッド
Publication of JP2019517523A publication Critical patent/JP2019517523A/ja
Publication of JP2019517523A5 publication Critical patent/JP2019517523A5/ja
Priority to JP2022191906A priority Critical patent/JP7431931B2/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2018563453A 2016-06-03 2017-06-02 肝線維症を治療する方法 Withdrawn JP2019517523A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022191906A JP7431931B2 (ja) 2016-06-03 2022-11-30 肝線維症を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345086P 2016-06-03 2016-06-03
US62/345,086 2016-06-03
PCT/US2017/035628 WO2017210526A1 (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022191906A Division JP7431931B2 (ja) 2016-06-03 2022-11-30 肝線維症を治療する方法

Publications (2)

Publication Number Publication Date
JP2019517523A true JP2019517523A (ja) 2019-06-24
JP2019517523A5 JP2019517523A5 (enExample) 2020-07-16

Family

ID=60479090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563453A Withdrawn JP2019517523A (ja) 2016-06-03 2017-06-02 肝線維症を治療する方法
JP2022191906A Active JP7431931B2 (ja) 2016-06-03 2022-11-30 肝線維症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022191906A Active JP7431931B2 (ja) 2016-06-03 2022-11-30 肝線維症を治療する方法

Country Status (15)

Country Link
US (3) US10682344B2 (enExample)
EP (1) EP3463350B1 (enExample)
JP (2) JP2019517523A (enExample)
KR (1) KR102444366B1 (enExample)
CN (2) CN115154467B (enExample)
AU (1) AU2017274521B2 (enExample)
BR (1) BR112018074452A2 (enExample)
CA (1) CA3025671C (enExample)
ES (1) ES2966111T3 (enExample)
IL (1) IL263245B (enExample)
MX (1) MX387070B (enExample)
RU (1) RU2740902C2 (enExample)
SG (2) SG11201810602YA (enExample)
WO (1) WO2017210526A1 (enExample)
ZA (1) ZA201807992B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
SG11201810602YA (en) * 2016-06-03 2018-12-28 Chemocentryx Inc Method of treating liver fibrosis
JP6678779B2 (ja) 2016-06-13 2020-04-08 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒ（ｎｒ１ｈ４）調節化合物
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
KR20190083659A (ko) * 2016-11-10 2019-07-12 갈메드 리서치 앤드 디벨롭먼트 리미티드 섬유증에 대한 치료
PT4122464T (pt) 2017-03-28 2024-06-27 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças do fígado
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
CN111406051A (zh) 2017-09-03 2020-07-10 安吉昂生物医药公司 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环
US11292785B2 (en) 2018-02-02 2022-04-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof
WO2019183004A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN113683597A (zh) * 2018-06-12 2021-11-23 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
CN112996490A (zh) * 2018-08-14 2021-06-18 阿沃林特有限公司 治疗原发性硬化性胆管炎的方法
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
US12102646B2 (en) * 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
SG11202107434PA (en) 2019-01-15 2021-08-30 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CN118388473A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
PE20220255A1 (es) 2019-05-08 2022-02-16 Aligos Therapeutics Inc Moduladores de thr y metodos de uso de estos
CN114207143A (zh) * 2019-07-30 2022-03-18 Ko生物技术有限公司 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法
JP7499841B2 (ja) 2019-07-30 2024-06-14 コバイオラブス，インコーポレーテッド 非アルコール性脂肪性肝疾患の予測若しくは診断用キット、および診断方法
WO2021102251A1 (en) * 2019-11-22 2021-05-27 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
CN113274368B (zh) * 2020-02-20 2023-08-22 甘莱制药有限公司 一种用于治疗脂肪性肝炎的药物组合物及其制备方法
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
MX2023003401A (es) * 2020-10-08 2023-04-25 Curome Biosciences Co Ltd Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo.
CN120899882A (zh) * 2025-06-16 2025-11-07 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) Klb蛋白在制备治疗血吸虫感染的药物上的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533203A (ja) * 2007-07-12 2010-10-21 ケモセントリックス， インコーポレイテッド 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
WO2016040860A1 (en) * 2014-09-12 2016-03-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118578A1 (en) * 2004-05-26 2005-12-15 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
EP2474532A1 (en) 2005-01-14 2012-07-11 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
US8067457B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
US20070219245A1 (en) * 2006-03-14 2007-09-20 Cuifen Hou Method of use for substituted dipiperidine ccr2 antagonists
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7683176B2 (en) * 2006-07-14 2010-03-23 Chemocentryx, Inc. Triazolyl pyridyl benzenesulfonamides
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
MX2011001911A (es) 2008-08-18 2011-07-04 Pfizer Anticuerpos para ccr2.
WO2011073154A1 (en) * 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
WO2012114223A1 (en) * 2011-02-25 2012-08-30 Pfizer Limited A method of treating liver fibrosis
US8658787B2 (en) * 2011-09-16 2014-02-25 Galectin Therapeutics Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
JP2015516404A (ja) * 2012-05-09 2015-06-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝疾患の処置のための合剤
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
SG11201810602YA (en) * 2016-06-03 2018-12-28 Chemocentryx Inc Method of treating liver fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533203A (ja) * 2007-07-12 2010-10-21 ケモセントリックス， インコーポレイテッド 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
WO2016040860A1 (en) * 2014-09-12 2016-03-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis

Also Published As

Publication number Publication date
AU2017274521B2 (en) 2021-08-19
US11357760B2 (en) 2022-06-14
CA3025671A1 (en) 2017-12-07
CN109475537A (zh) 2019-03-15
ES2966111T3 (es) 2024-04-18
IL263245B (en) 2021-09-30
EP3463350A4 (en) 2020-01-29
US20170348293A1 (en) 2017-12-07
EP3463350B1 (en) 2023-09-13
SG11201810602YA (en) 2018-12-28
US20200268727A1 (en) 2020-08-27
SG10202012080UA (en) 2021-01-28
KR102444366B1 (ko) 2022-09-19
KR20190026687A (ko) 2019-03-13
RU2018145459A (ru) 2020-07-09
WO2017210526A1 (en) 2017-12-07
JP2023022227A (ja) 2023-02-14
NZ748675A (en) 2024-12-20
BR112018074452A2 (pt) 2019-03-19
MX387070B (es) 2025-03-04
CN115154467B (zh) 2024-08-23
RU2018145459A3 (enExample) 2020-07-09
US10682344B2 (en) 2020-06-16
US20220313668A1 (en) 2022-10-06
EP3463350A1 (en) 2019-04-10
ZA201807992B (en) 2023-10-25
CA3025671C (en) 2024-10-01
IL263245A (en) 2018-12-31
AU2017274521A1 (en) 2018-12-13
CN115154467A (zh) 2022-10-11
MX2018014743A (es) 2019-04-11
RU2740902C2 (ru) 2021-01-21
JP7431931B2 (ja) 2024-02-15

Similar Documents

Publication Publication Date Title
JP7431931B2 (ja) 肝線維症を治療する方法
JP7518107B2 (ja) 巣状分節性糸球体硬化症を治療する方法
AU2006212761B2 (en) Combination therapy
JP7025781B2 (ja) ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
WO2020177587A1 (zh) 治疗脂肪性肝病和/或脂肪性肝炎的方法
JP2021503442A (ja) 中枢および末梢神経系障害の治療のためのキナーゼ阻害剤
CA3159601A1 (en) Methods for treating inflammatory bowel disease
HK40006091A (en) Method of treating liver fibrosis
WO2021177332A1 (ja) Ｎｌｒｐ３インフラマソーム阻害剤及び炎症性疾患の予防又は治療のための医薬組成物
HK40054971A (en) Method for treating fatty liver disease and/or steatohepatitis
BR112019010375B1 (pt) Usos de um composto no tratamento de glomeruloesclerose segmental focal primária

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221101

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222